Quarterly report pursuant to Section 13 or 15(d)

Goodwill (Tables)

v3.3.0.814
Goodwill (Tables)
 9 Months Ended
Sep. 30, 2015
Acquired Finite-Lived Intangible Assets [Line Items]  
Schedule of Acquired Finite-Lived Intangible Assets by Major Class [Table Text Block]
The net carrying value of the identifiable intangible assets as of September 30, 2015 is as follows: 
 
 
 
As of September 30, 2015
 
Life
 
Carrying
 
(Years)
 
Amount
Diagnostic assets:
 
 
 
Asuragen acquisition:
 
 
 
   Thyroid
9
 
$
8,519

   Pancreas
7
 
2,882

   Biobank
4
 
1,575

RedPath acquisition:
 
 
 
Pancreas test
7
 
16,141

Barrett's test
9
 
18,351

Total
 
 
$
47,468

Diagnostic lab:
 
 
 
CLIA Lab
2.3
 
$
609

 
 
 
 
Accumulated Amortization
 
 
$
(3,599
)
 
 
 
 
Net Carrying Value
 
 
$
44,478

Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]
Estimated amortization expense for the next five years is as follows, based on current assumptions of future product launches:
2015
2016
2017
2018
2019
$3,803
$6,328
$6,097
$5,949
$5,703